＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊GCSFIL-6BLC/CXCL13GM-CSFLeptinTGF-β1PARC/CCL18GROMCP-4/CCL13IL-5FGF-6IGFBP-1Flt-3 LigandSDF-1/CXCL12Eotaxin/CCL11FGF-9Fractalkine/CX3CL1MCSFIGFBP-4IL-3IGFBP-2IL-15TGF-β3IL-1αIL-4FGF-7IL-1βLIGHTIFN-γTNF-αIL-2AngiogeninCkβ8-1/CCL23MIG/CXCL9MCP-1/CCL2GCP-2/CXCL6MIFMCP-2/CCL8TIMP-2MIP-3α/CCL20HGFBDNFEotaxin-2/CCL24PDGF-BBGDNFGRO-α/CXCL1Eotaxin-3/CCL26FGF-4PIGFSCFTARC/CCL17OsteopontinMCP-3/CCL7MDC/CCL22RANTES/CCL5IL-7TNF-βVEGFOncostatin MTIMP-1NAP-2/CXCL7OsteoprotegerinNT-4ThrombopoietinIGF-I-2-1-3-4Log2(fold increase)MIG/CXCL9BLC/CXCL13IL-6LeptinGROGCSFPARC/CCL18IL-5MCP-4/CCL13IL-4FGF-6GM-CSFEotaxin/CCL11IL-3TGF-β1IGFBP-1AngiogeninIGFBP-4IP-10/CXCL10MCP-1/CCL2IGFBP-2SDF-1/CXCL12Flt-3 LigandMCP-2/CCL8Ckβ8-1/CCL23IL-7OsteopontinLIGHTFractalkine/CX3CL1FGF-4MCSFIL-1βTIMP-2GCP-2/CXCL6FGF-7FGF-9GDNFRANTES/CCL5IL-12TNF-αMIFIL-1αIL-2PDGF-BBIFN-γIL-15Eotaxin-2/CCL24TARC/CCL17MCP-3/CCL7TGF-β3IL-16NT-4Eotaxin-3/CCL26HGFIGF-IPIGFOsteoprotegerinMDC/CCL22MIP-1σ/CCL15BDNFSCFI-309/CCL1GRO-α/CXCL1IL-8/CXCL8MIP-1β/CCL4-3-2-1Log2(fold increase)Oncostatin MTNF-βIGFBP-3MIP-3α/CCL20NAP-2/CXCL7ENA-78/CXCL5VEGFIL-13TIMP-1NT-3ThrombopoietinLIFTGF-β2EGFIL-10IL-13IL-16MIP-1β/CCL4TGF-β2IP-10/CXCL10LIFMIP-1σ/CCL15NT-3IL-8/CXCL8IGFBP-3ENA-78/CXCL5EGFI-309/CCL1IL-12IL-10ベースライン (心筋炎群 vs 対照群)During ICIMyocarditis vs controlICI 後 (心筋炎群 vs 対照群)BaselineMyocarditis vs controlp<0.05p<0.05AB＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊0123401234＊図 4 ICI 心筋炎患者と対照患者におけるサイトカインの比較A ベースライン時のサイトカイン濃度の比較。B ICI 治療後のサイトカイン濃度の比較。Mann-Whitney U 検定。文献 17）より引用、改変。18
元のページ ../index.html#32